Skip to search formSkip to main contentSkip to account menu
  • Publications
  • Influence
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale
View on Elsevier
Pregabalin relieves symptoms of painful diabetic neuropathy
TLDR
In patients with diabetic peripheral neuropathy, pregabalin demonstrated early and sustained improvement in pain and a beneficial effect on sleep, which were confirmed by positive patient global impression.
View on Wolters Kluwer
Belinostat: First Global Approval
TLDR
Belinostat has received its first global approval as monotherapy for this indication in the US, under the Food and Drug Administration’s accelerated approval program.
View on Springer
Pembrolizumab: First Global Approval
TLDR
Pembrolizumab has received its first global approval for the treatment of advanced, unresectable or metastatic malignant melanoma in the US, for use in patients with disease progression after prior treatment with ipilimumab and a BRAF inhibitor.
View on Springer
Tofogliflozin: First Global Approval
TLDR
Tofogliflozin has received its first global approval for the treatment of type 2 diabetes mellitus in Japan as either monotherapy or in combination with other antihyperglcaemic agents.
View on Springer
Eliglustat: First Global Approval
TLDR
Eliglustat received its first global approval in this indication in the US, for use in treatment-naïve and treatment-experienced adult patients, and is also under regulatory review in the EU and Japan.
View on Springer
Ipragliflozin: First Global Approval
TLDR
Ipragliflozin is the first SGLT2 inhibitor to be approved in Japan, for use as monotherapy or in combination with another antihyperglycaemic agent.
View on Springer
Selective publication of antidepressant trials.
View on PubMed
Apremilast: First Global Approval
TLDR
Apremilast has received its first global approval for this indication in the USA and Regulatory submissions for approval in this indication are under review in Canada and Europe.
View on Springer
Frequency and severity of asymptomatic coronary disease in patients with different causes of stroke.
TLDR
Large-artery cerebrovascular disease, smoking, veteran status, and possibly left ventricular hypertrophy may be useful features for identifying patients with transient ischemic attack or stroke who are at highest risk of harboring asymptomatic CAD.
View on PubMed
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License